

Collaboration Opportunity: UKNEQAS ICC and ISH Mismatch Repair (MMR) Proteins EQA program

Germline mutations in DNA MMR proteins are one of the molecular fingerprints of Lynch syndrome; somatic mutations in these proteins are also associated with neoplastic conditions such as colorectal cancer and endometrial cancers. As more cancers are linked to these proteins, their importance as precision medicine biomarkers continues to grow.

Why join the collaboration:

- ✔ Receive sponsorship towards participation in this international EQA module in 2021. This module offers four assessment runs per year with the assessment of two paired antigens at each run. MLH1 & PMS2 OR MSH2 & MSH6 will be requested alternately.
- ✔ Gain confidence from an ISO:17043 accredited external body that MMR testing is being performed to a consistently high standard.

Please note: Sponsorship levels may vary depending on existing UKNEQAS ICC and ISH membership status

Additional information

To be eligible to participate in this collaboration please ensure that:

- ✔ Lab profile information reflects:
 - ⊗ Available in-house IHC auto-stainer details
 - ⊗ Which External Quality Assurance (EQA) modules or Proficiency Testing (PT) programs does your lab currently subscribe to for endometrial cancer and colorectal cancer
- ✔ Lab assay details reflecting
 - ⊗ At least 3 of the following molecular endometrial biomarkers
 - DNA mismatch repair proteins
 - p53
 - PTEN
 - p16
 - ARID1A
 - ⊗ Q1 & Q2 2020 volumes for the selected biomarker testing in endometrial cancer that is covered within your service

Please note that where multiple assays are available in-house, these must be logged as individual assays per technology

Collaboration process



Register interest on DXRX
Click register interest on DXRX



**Enrollment onto 2021 UKNEQAS ICC
and ISH Mismatch Repair (MMR)
Proteins EQA module**

Diaceutics will activate UKNEQAS ICC and ISH
EQA enrolment once eligibility is confirmed

[Discover DXRX Collaborations](#)